GLP-1s and Suicidality: The Largest UK Cohort Yet Finds No Added Risk
A new BMJ study using UK primary care data compared GLP-1 users head-to-head with other diabetes drugs — and the suicide-risk signal regulators have been chasing didn't show up.
If you've been on a GLP-1, considered one, or fielded the worried-mom phone call about one, you already know the question that won't go away: are these drugs messing with people's heads? Specifically — the one that's followed semaglutide around like a shadow since 2023 — are they nudging anyone toward suicidal thoughts? European and U.S. regulators opened formal reviews. Headlines did what headlines do. And the rest of us were left squinting at case reports, trying to figure out whether a real signal was buried in there or whether we were watching a very large, very anxious group of people being prescribed a very popular drug.
Now there's a serious piece of evidence to put on the table. A new study published in The BMJ used UK primary care records linked to hospital admissions and the national death registry to compare people newly started on GLP-1 receptor agonists against people newly started on two other classes of diabetes drugs — DPP-4 inhibitors and SGLT-2 inhibitors. The design is the kind regulators actually trust: an active comparator, new user cohort study, which is research-speak for “we compared real patients on Drug A to real patients on Drug B who looked a lot like them, starting from day one.”
The headline finding, in plain English: no increased risk of suicidal ideation, self-harm, or suicide among GLP-1 users compared with patients on the other two drug classes. That's the answer to the question people have been asking. It's also — and this is the part worth lingering on — not the same thing as “GLP-1s are proven safe for your mood, forever, full stop.” We'll get to why.
Why this study design matters more than the last twelve you read about
Most of the scary GLP-1/mental-health stories you've seen were built on a thinner kind of evidence: spontaneous adverse-event reports, where a patient or doctor flags something that happened while on a drug. Those reports are valuable as smoke detectors — they're how the original concern was raised — but they can't tell you whether the drug caused the event, or whether people prone to depression are simply more likely to be on a weight-loss medication in the first place.
An active-comparator new-user design tries to fix that. Instead of comparing GLP-1 users to the general population (apples to a fruit salad), the BMJ team compared them to people starting a different diabetes drug at the same point in their disease — patients with similar weight, similar blood sugar, similar prescribing histories. Then they used propensity-score weighting to balance the remaining differences, and followed both groups for suicidal ideation, self-harm, and suicide as recorded in primary care notes, hospital admissions, and death records.
It's not a randomized trial. It can't be. But for a question this specific, in a class of drugs this widely prescribed, it's about as close as observational research gets.
The study compared GLP-1 starters with people beginning DPP-4 or SGLT-2 drugs — a fairer head-to-head than comparing them with the general population.
The signal regulators have been chasing didn't show up in the data most likely to find it.
What they actually found
Across two large cohorts of patients with type 2 diabetes followed through March 2021, the authors reported no statistically significant increase in the composite outcome of suicidality — that's suicidal ideation, self-harm, and suicide considered together — among people on GLP-1 receptor agonists versus people on DPP-4 inhibitors or SGLT-2 inhibitors. The individual outcomes, looked at separately, didn't light up either.
For a class of drugs that's been prescribed to millions, that's the kind of finding that quietly moves the needle for regulators. It aligns with what the European Medicines Agency and the FDA had previously signaled after their own reviews: no causal link established. The BMJ paper is the kind of well-powered real-world analysis those agencies lean on when they're deciding whether to keep a warning on a label or take one off.
- The finding: No increased risk of suicidal ideation, self-harm, or suicide among GLP-1 users versus comparable patients on DPP-4 or SGLT-2 drugs.
- The design: An active-comparator, new-user cohort — the gold standard for real-world drug-safety questions short of a randomized trial.
- The population: UK adults with type 2 diabetes, not people taking GLP-1s purely for weight loss. Important caveat.
- The context: This is one strong study, not the final word. Evidence here is rated moderate, which is exactly how the language in this piece is calibrated.
- The takeaway for you: If you and your clinician are weighing a GLP-1, the suicidality concern is meaningfully less of a wildcard than it was a year ago — but mood is still worth tracking, as with any new medication.
What this study does NOT say (and why that matters for the rest of us)
Here's where I have to be the friend who reads the methods section so you don't have to. The BMJ cohort studied patients with type 2 diabetes. It did not study otherwise-healthy women in their forties using semaglutide or tirzepatide for weight management, perimenopausal metabolic shifts, or PCOS. Those are different populations, on potentially different doses, with different baseline mental-health profiles. The biological mechanism — GLP-1 acting on receptors in the brain — is presumably the same. The risk profile may not be identical.
The study also runs through March 2021, which predates the current tidal wave of off-label and weight-loss prescribing. And like every observational study, it can only measure what shows up in the records. Quieter symptoms — the low mood that doesn't make it into a chart note, the intrusive thought a patient never mentions — are harder to capture than a hospital admission for self-harm.
None of this undoes the finding. It just sets the lane. The signal regulators were chasing didn't show up in the data most likely to find it. That is genuinely reassuring. It is not a permission slip to ignore your own mood on a new medication.
Tracking mood the first few months on any new medication remains sensible — not because GLP-1s have been shown to cause harm, but because you're the best instrument for noticing changes in yourself.
How to hold this if you're on one — or thinking about it
If you're already on a GLP-1 and the headlines from 2023 made you uneasy, this is the kind of follow-up evidence worth knowing about. It doesn't erase the earlier concern; it contextualizes it. Drug-safety science is supposed to work like this — a signal goes up, the right studies get done, and the picture sharpens.
If you're weighing whether to start one, the mental-health question is now a smaller part of the conversation than it was. The bigger conversation — what GLP-1s do to muscle mass, what happens when you stop, who actually benefits long-term, what they cost — is the one to have with a clinician who knows your history. That's a conversation, not a verdict from a magazine. Including this one.
One large, well-built UK study isn't the end of this inquiry — more cohorts, in more populations, on longer follow-up, are coming. But it's a meaningful piece of the answer to a question that has hovered over the most prescribed drug class of the decade. For now, the most honest sentence is also the most useful one: the data we have don't show that GLP-1s raise suicide risk, and the study designed to find that signal didn't find it.
That's not a miracle-cure headline. It's better. It's the boring, careful kind of finding that lets the rest of the conversation — about benefits, trade-offs, and who these drugs are actually right for — finally happen on solid ground.